Physician profile
Amanda E Magee
NPI 1114091139
$967.19
in general payments reported to CMS, 2019-2025
10 companies · $96.51 in 2025
The $96.51 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $170 · 2022: $151 · 2023: $333 · 2024: $217 · 2025: $96.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $646.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $421.10 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Scilex Pharmaceuticals INC. | $160.41 | 2021-2024 | Ztlido |
| Boston Scientific Corporation | $84.30 | 2024 | Intracept |
| Nevro Corp. | $83.07 | 2021-2024 | Senza |
| Si-Bone, INC. | $75.14 | 2022-2023 | |
| Abbott Laboratories | $48.02 | 2025 | Eterna |
| Relievant Medsystems, INC. | $34.48 | 2023 | Intracept |
| Appliedvr INC | $27.20 | 2025 | Relievrx |
| Medtronic, INC. | $21.29 | 2025 | Inceptiv |
| Redhill Biopharma INC. | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Magee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.